Cardiol Therapeutics (CRDL) said in a regulatory filing Thursday that it has closed its public offering of 8,437,500 class A common shares at $1.60 per share for gross proceeds of $13.5 million.
The life sciences company said it plans to use the net proceeds to support the clinical development of CardiolRx to treat recurrent pericarditis, as well as for general and administrative expenses, working capital, and other expenses.
Shares of Cardiol Therapeutics were up 2.2% in recent premarket activity.
Price: 1.8191, Change: +0.04, Percent Change: +2.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments